By EMANUEL SARKEES
The United States is in the middle of what researchers are calling one of the most significant pharmacological developments in modern medicine. GLP-1 receptor agonists, the drug class behind Ozempic and Wegovy, have become able to reduce obesity, lower cardiovascular risk, control blood sugar, and show signals improving areas like addiction and dementia. It is backed by large scale clinical trials and is actively reshaping how physicians think about chronic disease management. The accessibility, however, is not keeping up with the science. The people who will benefit most from GLP-1s are the same people who have no path to receiving them.
This is not a coincidence. It is the outcome of a pricing structure, an insurance system, and a policy environment that have consistently made the same choice, which is to let cost determine who receives care.
What GLP-1s Actually Do
GLP-1s were originally developed to treat Type 2 diabetes. They work by acting similarly to a hormone the gut naturally produces after eating, which signals the brain to reduce appetite, slows digestion, and stabilizes blood sugar levels. The effects have been significant enough that the medical community’s interest has expanded well beyond diabetes management.
A 2023 clinical trial, known as the SELECT trial, found that semaglutide, the active ingredient in Wegovy, reduced the risk of cardiovascular issues like heart attacks and strokes by 20% in patients with obesity who did not have diabetes. That finding alone drew serious attention from cardiologists. Early research is also exploring GLP-1s in alcohol use disorder, sleep apnea, chronic kidney disease, and Alzheimer’s. The amount of potential application is unlike anything seen from a single drug class in recent times.
The Price Problem
The issue is not whether these drugs work. It is whether the system is built to let people use them. Wegovy, the FDA approved version specifically made for weight management, holds a price of around $1,300 per month in the United States without insurance coverage. Ozempic, technically approved for Type 2 diabetes but widely prescribed off label for obesity, runs at a similar cost. As one analysis noted, GLP-1 pricing “increased 442% between 2021 and 2023, creating a market three times larger than cancer spending, with list prices reaching $1,400”. Novo Nordisk and Eli Lilly, the two companies that dominate this market, charge American patients prices that are dramatically higher than what patients pay for the same medications in other countries.
The actual price a patient pays has very little to do with that $1,349 list price and almost everything to do with how they access the drug. With commercial insurance that covers obesity, costs can fall to around $25 a month, though that requires a plan that actually covers weight loss medications and prior authorization that actually gets approved. The Wegovy pill is available directly through NovoCare at $149 per month, the lowest price point ever for an FDA-approved GLP-1 weight loss medication. Zepbound starts at $299 per month through LillyDirect for patients who pay out of pocket. The government’s TrumpRx platform offers GLP-1s at around $350 per month for cash-paying patients who do not have coverage. Compounded versions through telehealth platforms like Ro and Hers run anywhere from $99 to $349 per month, though the FDA is actively restricting that market. And as of July 1, 2026, eligible Medicare beneficiaries can access Wegovy, Zepbound, and Foundayo at a flat $50 per month through the new Medicare GLP-1 Bridge program. That is a 27-times spread between the lowest and highest price for the exact same drug, determined not by what the medicine costs to make, but almost entirely by who you are when you walk up to the pharmacy counter. And for the uninsured, low income patient with no Medicare, no qualifying commercial plan, and no compounding option, none of those prices are on the table at all.
At $1,300 per month, the annual cost of Wegovy exceeds $15,000. For millions of Americans, that number is not just high, but is completely out of reach. That gap in pricing is not accidental. In countries where governments negotiate drug prices directly, the same medication costs a fraction of what Americans pay. The United States remains one of the only developed nations that does not regulate pharmaceutical pricing at the federal level, and patients suffer the difference.
Insurance coverage for GLP-1s follows a path that is both frustrating and familiar.
Most private insurers will cover these medications when prescribed for Type 2 diabetes. For obesity, even clinically severe obesity, the kind directly associated with cardiovascular disease and early mortality, coverage is inconsistent, frequently denied, and in many cases nonexistent. Medicare was prohibited from covering weight loss drugs for years, and while recent movements have begun to change that, the coverage aspect remains unresolved for a large portion of the population.
The contradiction here is hard to ignore. Insurers who decline to cover a $1,300 monthly medication are regularly paying for the hospitalizations, cardiac procedures, and diabetes complications that untreated obesity produces. The long term math does not support the denial, but the short term cost containment logic continues to make coverage decisions. What results is a system where the financial burden gets deferred rather than eliminated, and the patient absorbs the cost in the meantime.
Obesity in the United States disproportionately affects lower income populations and communities of color, the same populations that are most likely to be uninsured or underinsured. It reflects the same pattern shown across almost every dimension of American healthcare: the people who need the most support are consistently positioned with the least resources to receive it.
This is not a new observation, but GLP-1s make it very urgent. For a long time, the standard interventions for obesity, diet counseling, behavioral therapy, bariatric surgery, have each carried their own access barriers. GLP-1s were supposed to be different. A weekly injection, manageable side effects, dramatic results. Instead, the same economic wall that blocks access to everything else is blocking access to this too, and the populations most affected by obesity are once again left watching a solution exist just out of reach.
During a national shortage of semaglutide, compounding pharmacies began producing unregulated versions of the drug at lower price points, and a large number of Americans turned to them as an alternative. The quality and safety of those products varied greatly. The FDA has been steadily restricting that market, which means even the workaround that lower income patients relied on is narrowing. What remains is a coverage gap with no current policy designed to close it.
Where Things Stand
There are signs of movement, and one of them is genuinely significant. On July 1, 2026, Medicare launched the GLP-1 Bridge program, a pilot that gives eligible beneficiaries access to Wegovy, Zepbound, and Foundayo for obesity at a flat $50 monthly copay. For a drug that costs $1,300 a month at list price, that is a meaningful shift, and for millions of older Americans who have never had any coverage path for these medications, it represents something that did not exist before. But it is not enough, and it is worth being direct about why.
The $50 copay sounds accessible until you consider who Medicare’s lowest income beneficiaries actually are. A quarter of Medicare enrollees had incomes below $24,600 in 2024, and for someone living on a $750 monthly Social Security check, an extra $600 a year for a single prescription is not a minor expense. The low income subsidy program that normally reduces drug costs for the poorest beneficiaries does not apply to the Bridge program. And the program itself expires December 31, 2027, with no guaranteed path to permanent coverage after that.
Beyond Medicare, the picture is worse. Only 13 states currently cover GLP-1s for obesity under Medicaid, down from 16 states just a year ago, as budget pressures force states to pull back. For the uninsured working-age population, the compounded semaglutide that made the drug accessible at around $200 a month is being steadily restricted by the FDA, and no affordable replacement has emerged.
What would actually move the needle requires policy action on multiple fronts. The Treat and Reduce Obesity Act, which would permanently lift Medicare’s statutory ban on obesity drug coverage, has bipartisan support but has stalled over cost concerns despite studies projecting over $18 billion in healthcare savings over a decade. Medicaid coverage of GLP-1s for obesity needs to be made mandatory at the federal level rather than left to individual states to opt into and out of based on budget cycles. And federal drug price negotiation, which began in a limited way under the Inflation Reduction Act, needs to be extended aggressively to this drug class before the compounding window closes entirely.
The Medicare GLP-1 Bridge is a start. It is not a solution. A breakthrough that is accessible only to some Medicare beneficiaries for 18 months, in 13 states through Medicaid, and at $200 a month through a compounding market being shut down is not a healthcare policy. It is a placeholder. The drug exists, the evidence is overwhelming, and the cost of inaction keeps accumulating in emergency rooms and late stage diagnoses. What is missing is not the science. It is the political will to match access to what the medicine can actually do.
Emanuel Sarkees is a high school student with a strong interest in medicine, healthcare, and innovations that improve patient care and access to treatment
